Accessibility Menu
Oramed Pharmaceuticals logo

Oramed Pharmaceuticals(NASDAQ) ORMP

Current Price$4.02
Market Cap$164.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+2,277%
5 Year-70%
1 Year+93%
1 Month-6%
Oramed Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 4.032026-07-24
Oramed Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 4.032026-07-17
1 month-6.28%USD 4.302026-06-24
3 month+4.68%USD 3.852026-04-24
Year to date+51.68%USD 2.662025-12-31
1 year+92.99%USD 2.092025-07-24
3 year+47.04%USD 2.742023-07-25
5 year-69.98%USD 13.422021-07-23
Since inception+2,277.48%USD 0.172004-03-19

Oramed Pharmaceuticals Financials at a Glance

Market Cap

$164.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

$110.00M

EPS (TTM)

$2.58

P/E Ratio

1.56

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$4.02

Volume

3,799

Open

$4.16

Previous Close

$4.02

Daily Range

$3.97 - $4.16

52-Week Range

$1.98 - $5.19

Estimated Earnings Date

Aug 13, 2026

ORMP News

Scientist with head down

Why Oramed Pharmaceuticals Stock Is Crashing Today

Keith SpeightsJan 12, 2023
chalkboard

Why Oramed Pharmaceuticals Stock Is On Fire Today

George Budwell, PhDJul 12, 2022
piggybank rocket

Why Oramed Pharmaceuticals Stock Rocketed Higher Today

George Budwell, PhDJul 8, 2022

Oramed Pharmaceuticals: Monday’s Top Stock

Dave WilliamsonJan 27, 2014

Why Oramed Pharmaceuticals, Millennial Media, and Xoom Are Today's 3 Best Stocks

Sean WilliamsJan 27, 2014

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oramed Pharmaceuticals

Oramed develops oral capsules for diabetes and weight management. Its products aim to replace injections with pills for easier treatment. The company also invests in healthcare, technology, and real estate ventures.

Capsules, Cash, and Collaborations: Oramed’s Main Offerings

  • Oral Insulin Capsule (ORMD-0801): Pill form of insulin for diabetes; targets people needing daily injections. 100% of 2025 revenue from licensing this technology.
  • Oral GLP-1 Capsule (ORMD-0901): Capsule for type 2 diabetes; uses a hormone to help control blood sugar.
  • Oral Leptin Capsule: In development for weight loss; aims to help regulate appetite.
  • Licensing and Royalties: Earns income from licensing technology and sharing in product sales by partners.
  • Strategic Investments: Holds stakes in healthcare, biotech, and real estate companies for added income and diversification.

Plot Twists and Power Moves: Growth and Expansion

  • Transferred core oral delivery technology to Lifeward Ltd. in 2025, gaining equity and revenue-sharing rights.
  • Expanded investments in Alpha Tau Medical Ltd. (17% stake), Nano Dimension Ltd. (5.02%), and Pelthos Therapeutics (4.9%) between 2024-2025.
  • Launched Corner Ally Ventures in March 2026, a venture capital fund with a $40 million commitment.
  • Approved up to $30 million for real estate investments in Israel in 2025.
  • Formed joint ventures and licensing deals for product commercialization outside the U.S. since 2024.

Why Oramed Is a Bit Different

Oramed’s technology lets proteins, usually given by injection, be taken as pills. The company spreads risk by investing in other healthcare and real estate businesses. Its collaborative model brings in licensing income and shares development costs with partners.

Five Things You Need to Know

  • 2025 revenue was $2.0 million, up from $0 in 2024, all from licensing.
  • Net income reached $64.0 million in 2025, reversing a $19.1 million loss in 2024.
  • Operating loss was $15.1 million in 2025, up from $12.8 million in 2024.
  • Financial income rose to $89.5 million in 2025, mainly from investment revaluations.

Bottom Line

Oramed shifted from drug development to a mix of licensing and strategic investments. The company now balances healthcare innovation with diversified income streams.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

13

CEO

Nadav Kidron, MBA

Website

www.oramed.com

Headquarters

New York City, NY 10036, US

ORMP Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

55.29%

Return on Capital

-7.52%

Return on Assets

40.92%

Earnings Yield

64.10%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$164.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

40.93M

Volume

3.80K

Avg. Volume

303.96K

Financials (TTM)

Gross Profit

-$121.00K

Operating Income

-$14.25M

EBITDA

$78.84M

Operating Cash Flow

-$8.94M

Capital Expenditure

$192.68K

Free Cash Flow

-$8.74M

Cash & ST Invst.

$65.84M

Total Debt

$761.00K

Oramed Pharmaceuticals Performance Analysis

Oramed Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 2,703,0000.0%
20232023-12-31USD 1,340,000-50.4%
20242024-12-31USD 0N/A
20252025-12-31USD 2,000,000N/A
Oramed Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30-100.0%
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Oramed Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.9420.0%
20232023-12-31USD 0.14N/A
20242024-12-31USD -0.47N/A
20252025-12-31USD 1.50N/A
Oramed Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30263.2%
Q32025-09-30264.5%
Q42025-12-31-79.6%
Q12026-03-31295.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

-$30.00K

-330.8%

Gross Margin

0.00%

N/A

Market Cap

$164.93MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$12.69M

N/A

Employees

13

N/A

Net Income

$38.31M

+601.3%

EBITDA

-$3.63M

+18.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$65.84M

-49.6%

Total Debt

$761.00K

+152.8%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$493.00K

+310.8%

Short Term Debt

$268.00K

+48.1%

Return on Assets

40.92%

N/A

Return on Invested Capital

-5.52%

N/A

Free Cash Flow

-$2.92M

+17.1%

Operating Cash Flow

-$2.92M

+17.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
CNTBConnect Biopharma Holdings Limited
$2.14-2.73%
IFRXInflaRx N.V.
$1.74+0.58%
MGNXMacroGenics, Inc.
$3.70-7.73%
COYACoya Therapeutics, Inc.
$4.25-2.97%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$92.32-0.08%
NOKNokia
$9.10-0.06%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%

Questions About ORMP

What is the current price of Oramed Pharmaceuticals?

Oramed Pharmaceuticals is trading at $4.02 per share.

What is the 52-week range for Oramed Pharmaceuticals?

Over the past 52 weeks, Oramed Pharmaceuticals has traded between $1.98 and $5.19.

How much debt does Oramed Pharmaceuticals have?

As of the most recent reporting period, Oramed Pharmaceuticals reported total debt of $761.00K.

How much cash does Oramed Pharmaceuticals have on hand?

Oramed Pharmaceuticals reported $13.20M in cash and cash equivalents in its most recent financial results.

What is Oramed Pharmaceuticals’s dividend yield?

Oramed Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services